Relay Therapeutics Reports Promising Phase 2 Trial Results for Zovegalisib
Relay Therapeutics (RLAY) announced positive phase 2 trial results for zovegalisib in the treatment of vascular anomalies, leading to a stock price increase. The drug showed volumetric response rates of about 60% across various patient groups and mutations.
Topics: biotech cancer treatment drug development vascular anomalies